← All trials
NCT04457245
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 14, 2020
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Jul 7, 2020
- Last posted
- Jul 22, 2021
- Enrollment
- 312
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, Los AngelesLead sponsor
- ProgenicsCollaborator
- University of California, Los AngelesOverall official - principal investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.